In order to provide you with an optimal experience, we use technologies such as cookies to store and/or access device information. If you consent to these technologies, we may process data such as browsing behaviour or unique IDs on this website. If you do not give or withdraw your consent, certain features and functions may be affected.
Technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a particular service explicitly requested by the subscriber or user or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
a:2:{s:4:"text";s:0:"";s:4:"show";b:1;}
a:2:{s:4:"text";s:0:"";s:4:"show";b:1;}
Technical storage or access used solely for anonymous statistical purposes. Without a subpoena, voluntary consent from your Internet service provider, or additional records from third parties, information stored or accessed for this purpose cannot generally be used alone to identify you.
Technical storage or access is necessary to create user profiles, to send advertising or to track the user on a website or across multiple websites for similar marketing purposes.
Adult patients with acquired moderate Aplastic Anaemia (mAA) who have not received a specific treatment for their mAA may be included in the EMAA trial of Ulm University (Eltrombopag in Moderate Aplastic Anaemia). They receive either ciclosporin and eltrombopag or ciclosporin and a placebo. The aim of the trial is to evaluate the efficacy and safety of the combination therapy of ciclosporin and eltrombopag. Patients with or without prior transfusions can be included.
